ScholarIQanswers from OpenAlex & ORCID
Andrew X. Zhu
ResearcherPublications, citations & collaboration network
Andrew X. Zhu is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Andrew X. Zhu have?
ScholarIQindexed works
Andrew X. Zhu has 809 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Andrew X. Zhu have?
ScholarIQcitation count
Andrew X. Zhu has 80,480 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Andrew X. Zhu?
ScholarIQh-index
Andrew X. Zhu has an h-index of 116 in OpenAlex.
What is the i10-index of Andrew X. Zhu?
ScholarIQi10-index
Andrew X. Zhu has an i10-index of 342 in OpenAlex.
What is the ORCID of Andrew X. Zhu?
ScholarIQorcid
The ORCID for Andrew X. Zhu is on the source record.
What is the OpenAlex record for Andrew X. Zhu?
ScholarIQopenalex
The OpenAlex for Andrew X. Zhu is on the source record.
What are the most-cited papers on Andrew X. Zhu?
ScholarIQmost cited works
AASLD guidelines for the treatment of hepatocellular carcinoma
Julie K. Heimbach, Laura Kulik, Richard S. Finn, Claude B. Sirlin, Michaël Abécassis, Lewis R. Roberts, Andrew X. Zhu, M. Hassan Murad, Jorge A. Marrero
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu, Richard S. Finn, Julien Edeline, Stéphane Cattan, Sadahisa Ogasawara, Daniel H. Palmer, Chris Verslype, Vittorina Zagonel, Lætitia Fartoux, Arndt Vogel, Debashis Sarker, Gontran Verset, Stephen L. Chan, Jennifer J. Knox, Bruno Daniele, Andrea L. Webber, Scot Ebbinghaus, Junshui Ma, Abby B. Siegel, Ann‐Lii Cheng, Masatoshi Kudo, Angela Alistar, Jamil Asselah, Jean‐Frédéric Blanc, Ivan Borbath, Timothy Lewis Cannon, Ki Y. Chung, Allen Lee Cohn, David Cosgrove, Nevena Damjanov, Mukul Gupta, Yoshivasu Karino, Mark Karwal, Andreas Kaubisch, Robin Kate Kelley, Jena-Luc Van Laethem, Timothy Larson, James Lee, Daneng Li, Atisha Manhas, Gulam A. Manji, Kazushi Numata, Benjamin M. Parsons, Andrew Scott Paulson, Carmine Pinto, Robert A. Ramirez, Suresh Ratnam, Magnus Rizell, Olivier Rosmorduc, Yvonne H. Sada, Yutaka Sasaki, Per Stål, Simone I. Strasser, Joerg Trojan, Gina M. Vaccaro, Hans Van Vlierberghe, Alan Weiss, Karl-Heinz Weiss, Tatsuya Yamashita
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Andrew X. Zhu, Yoon‐Koo Kang, Chia‐Jui Yen, Richard S. Finn, Peter R. Galle, Josep M. Llovet, Eric Assénat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim, Kun‐Ming Rau, Kenta Motomura, Izumi Ohno, Philippe Merle, Bruno Daniele, Dong Bok Shin, Guido Gerken, Christophe Borg, Jean‐Baptiste Hiriart, Takuji Okusaka, Manabu Morimoto, Yanzhi Hsu, Paolo Abada, Masatoshi Kudo
Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial
Andrew X. Zhu, Joon Oh Park, Baek‐Yeol Ryoo, Chia-Jui Yen, Ronnie T. P. Poon, Davide Pastorelli, Jean-Frédéric Blanc, Hyun Cheol Chung, Ari David Baron, Túlio Pfiffer, Takuji Okusaka, Kateřina Kubáčková, Jörg Trojan, Javier Sastre, Ian Chau, Shao-Chun Chang, Paolo Abada, Ling Yang, Jonathan D. Schwartz, Masatoshi Kudo
Intrahepatic Cholangiocarcinoma: An International Multi-Institutional Analysis of Prognostic Factors and Lymph Node Assessment
Mechteld C. de Jong, Hari Nathan, Georgios C. Sotiropoulos, Andreas Paul, Sorin Alexandrescu, Hugo P. Marques, Carlo Pulitanò, Eduardo Barroso, Bryan M. Clary, Luca Aldrighetti, Cristina R. Ferrone, Andrew X. Zhu, Todd W. Bauer, Dustin M. Walters, T. Clark Gamblin, Kevin T. Nguyen, Ryan S. Turley, Irinel Popescu, Catherine Hubert, Stephanie Meyer, Richard D. Schulick, Michael A. Choti, J. F. Gigot, Gilles Mentha, Timothy M. Pawlik